Immunoliposome-based fluorometric patulin assay by using immunomagnetic nanoparticles

Song, Xinjie; Wang, Danhua; Kim, Myung‐Hee

doi:10.1007/s00604-019-3973-9

Cited by 16 publications

(2 citation statements)

References 31 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AT-liposomes primarily utilize specific interactions between ligands/receptors, antigens/antibodies, or molecules/receptors to deliver drugs to target sites. Among these AT-liposomes, those that are modified with monoclonal antibodies or fragments are also referred to as immunoliposomes . Compared with the features of passive-targeting liposomes, AT-liposomes have some additional special properties .…”

Section: Historymentioning

confidence: 99%

“…Among these AT-liposomes, those that are modified with monoclonal antibodies or fragments are also referred to as immunoliposomes. 55 Compared with the features of passivetargeting liposomes, AT-liposomes have some additional special properties. 32 For instance, the targeting of AT-liposomes is mainly determined by vascular-system permeability, tumor penetration, antigen density, ligand affinity, and binding-site barriers.…”

Section: ■ Historymentioning

confidence: 99%

See 1 more Smart Citation

Recent Advancements in Liposome-Targeting Strategies for the Treatment of Gliomas: A Systematic Review

Tan

Zhao

et al. 2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Malignant tumors represent some of the most intractable diseases that endanger human health. A glioma is a tumor of the central nervous system that is characterized by severe invasiveness, blurred boundaries between the tumor and surrounding normal tissue, difficult surgical removal, and high recurrence. Moreover, the blood–brain barrier (BBB) and multidrug resistance (MDR) are important factors that contribute to the lack of efficacy of chemotherapy in treating gliomas. A liposome is a biofilm-like drug delivery system with a unique phospholipid bilayer that exhibits high affinities with human tissues/organs (e.g., BBB). After more than five decades of development, classical and engineered liposomes consist of four distinct generations, each with different characteristics: (i) traditional liposomes, (ii) stealth liposomes, (iii) targeting liposomes, and (iv) biomimetic liposomes, which offer a promising approach to promote drugs across the BBB and to reverse MDR. Here, we review the history, preparatory methods, and physicochemical properties of liposomes. Furthermore, we discuss the mechanisms by which liposomes have assisted in the diagnosis and treatment of gliomas, including drug transport across the BBB, inhibition of efflux transporters, reversal of MDR, and induction of immune responses. Finally, we highlight ongoing and future clinical trials and applications toward further developing and testing the efficacies of liposomes in treating gliomas.

show abstract

Section: Historymentioning

confidence: 99%

Section: ■ Historymentioning

confidence: 99%